Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Merger or Acquisition (July 2014)
16 slides from Nicox Sa's merger presentation, Jul 2, 2014
Slide 1: Proposed acquisition of Aciex Therapeutics, Inc.
Proposed acquisition of Aciex Therapeutics, Inc. Building the therapeutic pipeline Conference Call July 2, 2014
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from t
Slide 3: Proposed Acquisition of Aciex Therapeutics
Proposed Acquisition of Aciex Therapeutics • Proposed acquisition by Nicox of Aciex Therapeutics, Inc., a private, U.S.-based pharmaceutical company • Aciex brings near-term pipeline of ophthalmic therapeutic candidates including AC-170 in phase 3 for allergic conjunctivitis and AC-155 for post-oper
Slide 4: Nicox at a glance
Nicox at a glance • Emerging international ophthalmic company with direct commercial operations in the United States and the five major European markets • Strategic partnership with global leader Bausch + Lomb on latanoprostene bunod in advanced phase 3 for glaucoma in the US • Growing portfolio of
Slide 5: Building a competitive global ophthalmic company
Building a competitive global ophthalmic company Proposed Aciex Additional business and RPS worldwide Sjö agreement for US Therapeutics corporate development agreement acquisition opportunities RetnaGene™ agreement for US 2012 2013 2014 2015 Potential extension of EuPharmed Potential EU product US d
Slide 6: Direct commercial presence in 6 major markets
Direct commercial presence in 6 major markets Eupharmed AdenoPlus® Sjö™ Xailin™ RetnaGene™ range ROW (third party distributors)1 1. Agreements already signed in Switzerland, Turkey, Benelux, South Africa, Poland 6
Slide 7: Comprehensive portfolio of diagnostics & therapeutics
Comprehensive portfolio of diagnostics & therapeutics Part 1: Nicox’s diagnostics portfolio Product Therapeutic Area Status Licensor (Territory) Diagnosis of Sjögren’s Sjö™ Launched in US in November 2013 (North America) Syndrome RetnaGene™ AMD risk evaluation Launched in US in June 2014 (North Amer
Slide 8: Comprehensive portfolio of diagnostics & therapeutics
Comprehensive portfolio of diagnostics & therapeutics Part 2: Nicox’s and Aciex’s therapeutics portfolio Product Therapeutic Area Research Pre-clinical Phase 1 Phase 2 Phase 3 Partners Xailin™1 Dry eye Marketed in EU and ROW (dist.) AC-170 (cetirizine Allergic conjunctivitis Pre-NDA meeting by Q1 20
Slide 9: Aciex: a pipeline of differentiated ophthalmic therapeutics
Aciex: a pipeline of differentiated ophthalmic therapeutics • Pipeline of differentiated therapeutics in ophthalmology • Several clinical-stage and pre-clinical products • Low relative risk: well-known molecules applied topically in the eye for the first time • Near-term product opportunities • AC-1
Slide 10: Aciex: AC-170 for allergic conjunctivitis
Aciex: AC-170 for allergic conjunctivis Addresses major market opportunity with established allergy molecule • AC-170 – novel formulation of cetirizine, leading and widely-used antihistamine developed for topical application in the eye for first time • Allergic conjunctivits represents major opportu
Slide 11: Aciex: AC-170 – two phase 3 studies completed
Aciex: AC-170 – two phase 3 studies completed Two phase 3 safety and efficacy studies have demonstrated statistically significant results for AC-170 over vehicle control for the primary endpoint of ocular itching. -0.92 -0.90 -0.87 -1.53 -1.34 -1.07 Gomes PJ, Raval Y, Schoemmell E, Welch DL.Evaluati
Slide 12: Aciex: AC-155 for postoperative pain and inflammation
Aciex: AC-155 for postoperative pain and inflammation Addresses major market opportunity with established steroid molecule • AC-155 – novel form of fluticasone, a leading corticosteroid, developed for the first time as a topical application in eye • Uses Aciex’s proprietary nanocrystallization manuf
Slide 13: Aciex: promising pipeline and technologies
Aciex: promising pipeline and technologies • Collaborative research agreement with Portola Pharmaceuticals, Inc. • Exclusive rights to jointly develop small molecule dual Syk1/JAK2 inhibitors for topical ophthalmic indications • Targeting ophthalmic diseases including ocular allergy, dry eye and oth
Slide 14: Aciex: proposed acquisition terms
Aciex: proposed acquisition terms • Nicox to acquire all outstanding shares in Aciex through reverse triangular merger under US laws and regulations • Cash-free debt-free basis • Aciex’s shareholders will receive: • An upfront payment of $65 million in newly-issued Nicox shares • Contingent value ri
Slide 15: Potential milestones and catalysts 2014-2015
Potential milestones and catalysts 2014-2015 Latanoprostene bunod: phase 3 results in glaucoma from Bausch + Lomb expected Q4 2014 AC-170: plan to request pre-NDA meeting with FDA by Q1 2015 Additional European product launches in 2014 and 2015 First launches from internal development program expect
Slide 16: Q&A session
Q&A session www.nicox.com Nicox S.A. | Nicox Pharma Nicox Inc. Nicox Research Institute S.r.l. Drakkar 2 – Bât D 777 Main Street | Suite 2160 Via Ariosto 21 2405 Route des Dolines Fort Worth | Texas 76102 20091 Bresso | Milano CS 10313 Sophia Antipolis Italy T: +1 817 529 9300 06560 Valbonne | Franc